Status of Cancer Research Worldwide

Newswise — Leading scientists from prestigious institutions around the world will convene in New York to report on the remarkable progress of their cancer research projects. Their findings will be highlighted at this press conference. Monday, May 7, 20075:30pmVersailles Room, St. Regis Hotel2 East 55th Street at Fifth Avenue, New York City "21st Century Science has Drastically Changed the Face & Pace of Cancer Research and Has Started to Deliver the Cure"

Success in curing certain forms of cancer has been attained and great progress has been made in providing scientific-based drug therapies that treat many forms of cancer. The press conference and scientific review will give specific examples of breakthroughs, including one that has helped cure 50,000 people. Listed below are a few of more than three dozen international participants:Mount Sinai, Memorial Sloan Kettering; Center for Cancer Research; National Institutes of Health; Johns Hopkins; The Salk Institute; GlaxoSmithKline; Shanghai Institute of Hematology; Dartmouth; Weizmann Institute - Israel; Institute of Cancer Research - London. NOTE: The press conference segment is officially over at 6:30, but editors are invited to remain for the entire SWCRF Annual Scientific Review. The Scientific Advisory Committee will present their progress report to supporters and there will be opportunities for one-on-one and small group discussions with renowned scientists from around the world.

About SWCRFNow in its 32nd year, the Samuel Waxman Cancer Research Foundation (SWCRF) is affiliated with The Mount Sinai Medical Center in New York City. Its "Institute Without Walls" is a unique non-profit international organization dedicated to supporting focused concept-driven research to develop targeted cancer cell-specific therapies, such as differentiation therapy. Two drugs developed through Foundation-supported research, and now used worldwide, have proven the effectiveness of non-toxic differentiation in the treatment of acute promyelocytic leukemia (APL), which has helped cure 50,000 people.The Foundation funds highly collaborative research groups throughout the United States, Canada, China, Europe and Israel. SWCRF grant applicants are established investigators who agree to collaborate with other SWCRF investigators on research projects funded by the Foundation. For more information, visit http://www.waxmancancer.org